The ATP5A1 antibody has been instrumental in studying its role in cancer progression. For example:
Cervical Cancer: ATP5A1 overexpression was shown to promote apoptosis and regulate alternative splicing of oncogenic genes (e.g., MMP2, MMP19) in HeLa cells, suggesting its tumor-suppressive potential .
Clear-Cell Renal Cell Carcinoma (ccRCC): Low ATP5A1 expression correlated with poor prognosis and aggressive tumor behavior, with the antibody validating its downregulation in ccRCC cell lines .
In zebrafish, ATP5A1 exhibits antibacterial activity, protecting embryos from pathogens like Aeromonas hydrophila. The antibody confirmed its presence in embryonic lysates and demonstrated its role in membrane depolarization/permeabilization .
The antibody serves as a loading control for mitochondrial proteins in studies investigating Complex V activity. For instance, it was used to normalize mitochondrial protein levels in colon cancer cells treated with SIRT3 inhibitors .
Alternative Splicing: ATP5A1 regulates splicing of genes involved in glucose metabolism and HIF-1 signaling, impacting cancer progression .
Wnt/β-Catenin Pathway: Its downregulation in ccRCC correlates with pathway activation, suggesting a suppressive role .
While ATP5A1’s role in mitochondrial ATP synthesis is conserved, its immune function in zebrafish embryos underscores evolutionary divergence in its biological roles .
The antibody has been validated in 126 WB, 4 IHC, and 19 IF studies across diverse tissues and cell lines (e.g., 786-O, CAKI-1 renal cancer cells) . Its specificity is further supported by co-immunoprecipitation (CoIP) assays targeting mitochondrial complexes .
Applications : Western blot
Sample type: tissues
Review: anti ATP5F1A was obtained from CUSABIO.(Complex V, PA002344HA01HU; CUSABIO, China).